Anti-human and human igf-ir her2 bispecific antibodies and methods of use, and

The present invention provides a bispecific antibody against human HER2 and human IGF-IR comprising a first antigen that specifically binds HER2 binding domain and a second binding specificity to IGF-IR antigen binding domains, a first and second antigen against binding domain consists of a heavy chain variable domain (VH) and an antibody light chain variable domain (VL) composition; first antigen binding domain of an antibody variable region domain capable of binding specifically to HER2; second antigen-binding domain is a variable region domain may be an antibody that specifically binds to IGF-IR. Preparation includes: Synthesis of cDNA sequences encoding the antibody; the cDNA sequence inserted into the tool-carrier, construction of expression vectors; expression and bispecific antibodies Purification expressed in a host cell the expression vector. The present invention for preparing treatment of human cancers, especially in human breast cancer drugs.